WST stock jumps on Q1 earnings & sales beat, EPS view up on HVP growth

robot
Abstract generation in progress

West Pharmaceutical Services (WST) reported stronger-than-expected Q1 earnings and sales, with adjusted EPS of $2.20 on revenues of $754.7 million, driven by growth in its High-Value Products (HVP) portfolio. The company raised its full-year 2024 adjusted EPS guidance to $7.70-$7.90 and maintained its sales forecast, reflecting confidence in its HVP segment and favorable foreign currency movements. Despite a slight decrease in overall sales, the robust performance of HVP and improved margins contributed to the positive financial outlook.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin